Physician profile
Suparna Mullick
NPI 1366547713
$4,672.23
in general payments reported to CMS, 2019-2025
29 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $537 · 2021: $572 · 2022: $591 · 2023: $596 · 2024: $791 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.07 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.60 | 2019-2025 | |
| Pfizer INC. | $572.25 | 2019-2025 | |
| Janssen Biotech, INC. | $552.43 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $366.88 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $310.74 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $263.43 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $250.54 | 2024 | Vtama |
| Mayne Pharma Commercial LLC | $229.93 | 2019-2025 | |
| Lilly USA, LLC | $173.37 | 2019-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $155.36 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $125.47 | 2022-2025 | Dupixent |
| Organon LLC | $124.41 | 2025 | Vtama |
| Ucb, INC. | $112.19 | 2020-2021 | |
| Leo Pharma INC. | $109.36 | 2022-2025 | Anzupgo, Adbry |
| Novartis Pharmaceuticals Corporation | $90.86 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $82.65 | 2019-2022 | |
| Incyte Corporation | $78.32 | 2024-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.52 | 2022-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $46.01 | 2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.82 | 2019-2020 | |
| Biofrontera INC. | $37.11 | 2021-2024 | Rhodoled Xl, Ameluz, Xepi |
| Genentech USA, INC. | $21.25 | 2022 | |
| Verrica Pharmaceuticals INC. | $17.15 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $16.13 | 2020 | |
| Fresenius Kabi USA, LLC | $15.10 | 2024 | Idacio |
| Sandoz INC. | $12.61 | 2020 | |
| Merck Sharp & Dohme LLC | $11.97 | 2019 | |
| Allergan, INC. | $11.74 | 2021 | |
| Taro Pharmaceuticals USA, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suparna Mullick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.